Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to Mtb

Area of Science:

• * Infectious Diseases
• * Immunology
• * Pharmacology

Background:

• * Current tuberculosis (TB) treatments face challenges from drug-resistant Mycobacterium tuberculosis (Mtb).
• * Metformin is being explored as an adjunctive therapy, but its effects on Mtb-macrophage interactions are not well understood.
• * Understanding metformin's impact on Mtb within host cells is crucial for developing new treatment strategies.

Purpose of the Study:

• * To characterize how metformin influences Mtb growth within macrophages.
• * To investigate metformin's effects in combination with isoniazid, a first-line anti-TB drug.
• * To elucidate the mechanisms by which metformin modulates the host-pathogen interaction.

Main Methods:

• * Live cell tracking using time-lapse microscopy to monitor Mtb infection dynamics.
• * Assessment of metformin's effect on Mtb growth in macrophages.
• * Comparison of metformin with isoniazid, both alone and in combination.

Main Results:

• * Metformin treatment resulted in a 14.2-fold decrease in Mtb growth compared to untreated controls.
• * The combination of metformin and isoniazid showed slightly improved Mtb growth control compared to isoniazid alone.
• * Metformin effectively regulated cytokine and chemokine responses over 72 hours, outperforming isoniazid alone.

Conclusions:

• * Metformin controls Mtb growth by enhancing host cell viability and inducing a pro-inflammatory response.
• * Metformin demonstrates potential as a host-directed adjunctive therapy for TB.
• * Further research into metformin's role in TB treatment can lead to novel therapeutic approaches.